Search review questions

0.5% CMC vs. sodium hyaluronate · people with dry eye

0.5% CMC vs. 0.3% HPMC · people with dry eye

0.5% CMC vs 1% CMC · people with dry eye

lipid‐based CMC vs. aqueous‐based CMC · people with dry eye

Two different concentrations of CMC + hyaluronic acid vs CMC · people with dry eye

0.5% CMC vs 0.5% CMC + castor oil vs. 1.0% glycerine + castor oil · people with dry eye

1.0% CMC vs. 0.18% sodium hyaluronate · people with dry eye

1.0% CMC vs. 0.3% HPMC · people with dry eye

1.0% CMC vs. 0.4% carbomer · people with dry eye

a) · people with dry eye

0.2% carbomer vs. 0.3% HPMC vs. 0.3% anhydrous liquid lanolin · people with dry eye

0.2% carbomer vs. HP‐guar · people with dry eye

0.3% carbomer vs. 0.18% sodium hyaluronate · people with dry eye

Carbomer gels containing different preservatives · people with dry eye

0.2% PAA vs. 1.4% PVA · people with dry eye

1.4% PVA vs. 0.1% sodium hyaluronate · people with dry eye

1.4% PVA vs. carbomer · people with dry eye

0.3% HPMC vs. 0.4% hyaluronic acid · people with dry eye

Two different products containing 0.3% HPMC · people with dry eye

0.3% HPMC with vs without bicarbonate · people with dry eye

b) · people with dry eye

0.3% HPMC vs. 1.25% castor oil · people with dry eye

Trehalose + hyaluronic acid vs. PEG + PG + HP‐guar · people with dry eye

c) · people with dry eye

PEG 400 + PG + HP‐guar vs. CMC · people with dry eye

PEG 400 + PG or sodium hyaluronate vs. HPMC or CMC · people with dry eye

0.4% PEG 400 + PG vs. 0.25% PEG 400 · people with dry eye

0.25% PEG 400 vs.1% CMC · people with dry eye

0.25% PEG 400 vs. 0.3% HPMC · people with dry eye

Complete success ( · People undergoing trabeculectomy surgery with glaucoma

Qualified success ( · People undergoing trabeculectomy surgery with glaucoma

Mean IOP ( · People undergoing trabeculectomy surgery with glaucoma

Adverse events ‐ wound leaks · People undergoing trabeculectomy surgery with glaucoma

Adverse events ‐ hypotony · People undergoing trabeculectomy surgery with glaucoma

Adverse events ‐ shallow anterior chamber · People undergoing trabeculectomy surgery with glaucoma

Adverse events ‐ endophthalmitis · People undergoing trabeculectomy surgery with glaucoma

UCVA of 20/20 or better at 12 months post treatment · adult participants (≥ 18 years) with myopia

Within ± 0.50 D of target refraction at 12 months post treatment · adult participants (≥ 18 years) with myopia

Loss of 1 or more lines of BSCVA at 12 months post treatment · adult participants (≥ 18 years) with myopia

Mean spherical equivalent at 12 months post treatment · adult participants (≥ 18 years) with myopia

Adverse outcomes ‐ corneal haze score at 12 months (grade 1.0 ‐ more prominent haze that does not interfere with visibility of fine iris details; grade 2.0 ‐ mild obscuration of iris details; grade 3.0 ‐ moderate obscuration of iris and lens; and ... · adult participants (≥ 18 years) with myopia

Adverse outcomes ‐ glare and halo scores at 3 months (grade 0 ‐ none; grade 1 ‐ very low; grade 2 ‐ low; grade 3 ‐ moderate; grade 4 ‐ high; and grade 5 ‐ very high) · adult participants (≥ 18 years) with myopia

Proportion of successful procedures at 1 year and up to 5 years after surgery (no exposure/extrusion) · people with anophthalmic sockets

Socket and prosthesis motility (horizontal) · people with anophthalmic sockets

Socket and prosthesis motility (vertical) · people with anophthalmic sockets

Any adverse outcomes (e.g. extrusions or migration, infections, ectropion) · people with anophthalmic sockets

Improvement in visual impairment at 6 months · people residing in communities endemic for onchocerciasis

Parasitological outcomes · people residing in communities endemic for onchocerciasis

Clinical outcomes: improvement in optic atrophy, chorioretinitis, or sclerosing keratitis at 6 months · people residing in communities endemic for onchocerciasis

Clinical outcomes: improvement in iridocyclitis at 6 months · people residing in communities endemic for onchocerciasis